Tag Archives: media

Global Neuroscience Antibodies & Assays Market : Industry Analysis and Forecast (2020-2027) By Product, Technology, Application, End User,and…

Global Neuroscience Antibodies & Assays Market 2019 TO 2027:

Maximize Market Research has recently added a new research report to its mega database of research studies. The research report, titled Global Neuroscience Antibodies & Assays Market 2019 Industry Research Report, gives an exhaustive analysis of the current market, including an overview, Neuroscience Antibodies & Assays products segmentation, market restraints and drivers, and major geographical segments.

The Neuroscience Antibodies & Assays market analysis also encompasses the competitive outlook of the world Neuroscience Antibodies & Assays market, furnishing the detailed profiles of the major market players. The important insights and recommendations by Neuroscience Antibodies & Assays industry adepts would definitely guide the players in persuasively establishing their strategies and policies and achieve a competitive edge in the Neuroscience Antibodies & Assays business.

Additionally, the Neuroscience Antibodies & Assays market 2019 report diagnosis the competitive layout of the world Neuroscience Antibodies & Assays market, comprising an outline of the major industry players, followed by their business strategies, policies, financial aspects and current market developments.

Request For View Sample Neuroscience Antibodies & Assays Market Report Page : https://www.maximizemarketresearch.com/request-sample/79832

The report emphasis on the Top Manufacturers in the world Neuroscience Antibodies & Assays market, with profits, losses, prices, production, and market share for each and every manufacturer, covering: Businesses.

Scope of the Global Neuroscience Antibodies & Assays Market

Global Neuroscience Antibodies & Assays Market, By Product

Consumableso Reagents Media & Sera Stains & Dyes Fixatives Buffers Solvents Probes Enzymes, Proteins, & Peptides Other Reagentso Antibodies Primary antibodies Secondary Antibodieso Assay Kits Instrumentso Microplate Readerso Immunoassay Analyzerso Other InstrumentsGlobal Neuroscience Antibodies & Assays Market, By Technology

Immunochemistry/Immunoassayso ELISAo Western Blottingo Others Immunoassays Technologies Molecular Diagnostics Clinical Chemistry Other TechnologiesGlobal Neuroscience Antibodies & Assays Market, By Application

Research In Vitro Diagnostics Drug Discovery and DevelopmentGlobal Neuroscience Antibodies & Assays Market, By End User

Pharmaceutical & Biotechnology Companies Academic & Research Institutes Hospitals & Diagnostic CentersGlobal Neuroscience Antibodies & Assays Market, By Region

North America Europe Asia Pacific Middle East & Africa South AmericaKey players operating in the Global Neuroscience Antibodies & Assays Market

Thermo Fisher Scientific Abcam Bio-Rad Merck KGaA BioLegend Cell Signaling Technology F. Hoffmann-La Roche GenScript Rockland Immunochemicals Santa Cruz Biotechnology Siemens Tecan OthersDetailed SWOT analysis of these players has also been included in the Neuroscience Antibodies & Assays market report to determine the threats and opportunities faced by them while operating in the Neuroscience Antibodies & Assays industry.

Do Inquiry Before Purchasing Market Neuroscience Antibodies & Assays Report Here : https://www.maximizemarketresearch.com/inquiry-before-buying/79832

The Neuroscience Antibodies & Assays market 2019 industry research study further analyzes the global Neuroscience Antibodies & Assays industry in terms of revenue and has presented the historical data and forecast figures with the help of tables, charts, and infographics. The Neuroscience Antibodies & Assays report also provides a comprehensive analysis of the global Neuroscience Antibodies & Assays market with the help of several analytical tools and helps in determining the growth prospects and opportunities of the Neuroscience Antibodies & Assays industry. It also helps in understanding the major factors that affect the structure and profitability of the global Neuroscience Antibodies & Assays industry.

Browse Complete Neuroscience Antibodies & Assays Report details with ToC and List Of Figures Here:

Table of Contents

Browse Full Report with Facts and Figures of Neuroscience Antibodies & Assays Market Report at:https://www.maximizemarketresearch.com/market-report/global-neuroscience-antibodies-assays-market/79832/

About Us:

Maximize Market Research provides B2B and B2C market research on 20,000 high growth emerging technologies & opportunities in Chemical, Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors .

Contact info:

Name: Vikas Godage

Organization: Maximize Market Research .

Email: [emailprotected]

Contact: +919607065656 / +919607195908

Website: http://www.maximizemarketresearch.com

https://neighborwebsj.com/

More here:
Global Neuroscience Antibodies & Assays Market : Industry Analysis and Forecast (2020-2027) By Product, Technology, Application, End User,and...

BioXcel Therapeutics to Present an Update from its Ongoing Trial of BXCL701 in Aggressive Forms of Prostate Cancer at the 2021 ASCO Genitourinary…

NEW HAVEN, Conn., Feb. 04, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. ("BioXcel" or the "Company") (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that an update from its ongoing Phase 1b/2 trial of BXCL701, the Company's investigational, oral innate immunity activator, in aggressive forms of prostate cancer will be presented in a poster session at the virtual 2021 ASCO Genitourinary ("ASCO GU") Cancers Symposium. ASCO GU is being held from Thursday, February 11, 2021 to Saturday, February 13, 2021.

Poster Presentation Details: Title: BXCL701, first-in-class oral activator of systemic innate immunity pathway, combined with pembrolizumab (Keytruda) in men with metastatic castration-resistant prostate cancer (mCRPC)Poster Session: Prostate Cancer - AdvancedTime: Available starting on February 11, 2021 at 8:00 a.m. Eastern TimeAbstract Number: 124

The abstract will be available on the ASCO GU website at meetinglibrary.asco.org/ on Monday, February 8, 2021 at 5:00 p.m. ET. At the start of the poster session, the poster will be available in the News & Media section of the Companys website at http://www.bioxceltherapeutics.com.

About BXCL701

BXCL701 is an investigational orally administered innate immune activator designed to initiate inflammation in the tumor microenvironment. Approved and experimental immunotherapies often struggle to address cancers that appear "cold" or uninflamed. Therefore, BXCL701 may render "cold" tumors "hot," making them more detectable by the adaptive immune system and thereby facilitating the development of a strong anti-cancer immune response. BTI's preclinical data supports BXCL701's synergy with both current checkpoint inhibitor-based therapies and emerging immunotherapies directed to activate T-cells, such as IL-2.

This candidate is currently being developed as therapy for aggressive forms of prostate cancer ("cold" tumor) and advanced solid tumors that are refractory or treatment nave to checkpoint inhibitors ("hot" tumors).

BioXcel Therapeutics, Inc.

BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on drug development that utilizes artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. BioXcel's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. BioXcel's two most advanced clinical development programs are BXCL501, an investigational, proprietary, orally dissolving thin film formulation of dexmedetomidine for the treatment of agitation and opioid withdrawal symptoms, and BXCL701, an investigational, orally administered, systemic innate immunity activator in development for the treatment of aggressive forms of prostate cancer and advanced solid tumors that are refractory or treatment nave to checkpoint inhibitors. For more information, please visit http://www.bioxceltherapeutics.com.

Contact Information:

BioXcel Therapeutics, Inc.

http://www.bioxceltherapeutics.com

Investor Relations:

Mary ColemanBioXcel Therapeutics, VP of Investment RelationsMColeman@bioxceltherapeutics.com1.475.238.6837

John GrazianoSolebury Troutjgraziano@soleburytrout.com1.646.378.2942

Media:

Julia DeutschSolebury Troutjdeutsch@soleburytrout.com1.646.378.2967

Go here to read the rest:
BioXcel Therapeutics to Present an Update from its Ongoing Trial of BXCL701 in Aggressive Forms of Prostate Cancer at the 2021 ASCO Genitourinary...

Samsung Bioepis Opens the New State-of-the-Art Headquarters to Accommodate Next Stage of Growth and Innovation – BioSpace

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/370961b4-344f-49bf-86e4-e882f7265b1c

INCHEON, Korea, Jan. 25, 2021 (GLOBE NEWSWIRE) -- Samsung Bioepis Co., Ltd. today announced the opening of its new headquarters in Koreas Bio Cluster of Songdo, located in the Incheon Free Economic Zone (IFEZ), a specially-designated economic zone in the city of Incheon. The new site is approximately 52,000 square feet, and will be the hub of Samsung Bioepis drive for development of next-generation biologic medicines. Construction of the new building was completed in December 2020.

We are very excited to be opening our new headquarters which will serve as the foundation for the companys next stage of growth. Our colleagues who were previously stationed in two campuses in Korea will be working together at the new headquarters to accelerate our passion for health, said Christopher Hansung Ko, President and Chief Executive Officer, Samsung Bioepis. With the new office equipped with the state-of-the-art laboratories, we look forward to providing our high-quality biologic medicines with more agility and with stringent quality control so that patients around the world can have access to our proven medicines more quickly and more widely available.

The newly established 12-story building will house approximately 1,000 employees, who will be working at the 17,300-square-foot laboratory space and 15,200-square-foot office space. Attached to the main building is a three-story Welfare Center which includes 4,750-square-foot cafeteria, a gymnasium and a fitness center for employees to enjoy. Furthermore, the company has an onsite childcare center to support employees with young children.

Established in 2012, Samsung Bioepis has rapidly grown to have five biologic products in immunology and oncology with more than 215,000 patients treated with the companys immunology products in Europe alone. The company is continuing its work to improve access to medicines through its unique process innovation development platform and currently has five biologic candidates in its pipeline ranging from hematology and ophthalmology.

About Samsung Bioepis Co., Ltd.

Established in 2012, Samsung Bioepis is a biopharmaceutical company committed to realizing healthcare that is accessible to everyone. Through innovations in product development and a firm commitment to quality, Samsung Bioepis aims to become the world's leading biopharmaceutical company. Samsung Bioepis continues to advance a broad pipeline of biosimilar candidates that cover a spectrum of therapeutic areas, including immunology, oncology, ophthalmology and hematology. Samsung Bioepis is a joint venture between Samsung Biologics and Biogen. For more information, please visit: http://www.samsungbioepis.com and follow us on social media Twitter, LinkedIn.

MEDIA CONTACTYoon Kim: yoon1.kim@samsung.com

Samsung Bioepis New Headquarters

Samsung Bioepis

Read more:
Samsung Bioepis Opens the New State-of-the-Art Headquarters to Accommodate Next Stage of Growth and Innovation - BioSpace

Nirogy Therapeutics Launches with $16.5 Million Series A FinancingProceeds to support the development of small-molecule drugs that modulate the…

BOSTON, Jan. 26, 2021 (GLOBE NEWSWIRE) -- Nirogy Therapeutics Inc., a privately-held biotechnology company developing novel small molecules to target cellular transporters, today announced the closing of a $16.5 million Series A financing. The financing was co-led by Sant Ventures and Sporos. In conjunction with the financing, Dennis McWilliams of Sant and Joseph Kekst of Sporos will join Nirogys board of directors, and Casey Cunningham, Ph.D. will join Nirogys scientific advisory board.

Nirogy plans to use the proceeds to advance its drug discovery platform to generate a pipeline of small-molecule drugs designed to target the solute carrier family of transporter proteins (SLCTs) embedded in the cell membrane. SLCTs are gatekeepers of essential physiological functions, including nutrient uptake and metabolite disposal, which are aberrantly altered in many diseases. Enabled by its proprietary small-molecule compound library and rapid development strategies, Nirogy is developing first-in-class medicines with an initial focus on oncology and autoimmune diseases.

Cellular transporters, which are central to many aspects of cell biology and dysregulated in myriad diseases, have not been effectively targeted due to the complex structures of SLCTs. Our teams strength in computational modeling, medicinal chemistry and cancer biology has enabled us to overcome the challenge of drugging these critical untapped targets, said Vincent Sandanayaka, Ph.D., founder, president and chief executive officer of Nirogy Therapeutics. We are fortunate to have a world-class scientific advisory board, highly committed investor partners and a dedicated team with proven scientific and drug development expertise.

Nirogys lead program targets lactate transporters for the treatment of cancer and is expected to enter human clinical trials in 2022. Unlike normal cells, cancer cells consume large amounts of glucose and excrete a huge excess of lactic acid to the tumor microenvironment via lactate transporters for their rapid growth and survival. Lactate-rich tumors create a hostile environment for immune cells to survive, thus suppressing anti-tumor immunity. Nirogys lactate transport inhibitors have shown robust anti-tumor efficacy in preclinical models, either as monotherapy or combination therapy. Nirogys pipeline also includes a second transporter target in cancer and a third program in immunology.

Dennis McWilliams, partner at Sant Ventures, said: We recognize the potential of the Nirogy team and its proprietary drug discovery engine in SLCTs, which could yield over 450 potential druggable targets and open up new treatment modalities for a number of life-threatening diseases.

Ronald DePinho, M.D., Nirogy co-founder and chair of the Sporos strategic advisory board, added: It is a privilege to work with this incredible team thats focused on revealing the mysteries of cellular transport biology and converting such insights into medicines for our patients in need.

ABOUT NIROGY

Nirogy Therapeutics is a biotechnology company based in Boston, MA developing novel small molecules to target cellular transporters. The company is currently advancing a class of small molecules intended to disrupt metabolic and immune mechanisms operative in the tumor microenvironment. Follow-on platform programs are targeting additional disease pathways in oncology as well as autoimmune diseases.

For more information, please visitnirogytx.com.

ABOUT SANTE VENTURES

Founded in 2006, Sant Ventures is a specialized healthcare and life sciences investment firm with over a half-billion dollars in capital under management. The firm invests in early-stage companies developing innovative new medical technologies, biotechnologies, and digitally enabled healthcare services. Recent Sant successes include Claret Medical (Boston Scientific), TVA Medical (Becton Dickinson), Millipede Medical (Boston Scientific), Molecular Templates (MTEM), AbVitro (Celgene), and Explorys (IBM Corp). Sant invests nationally and has offices inAustin, TX andBoston, MA.For more information, please visitsante.com.

MEDIA CONTACT:

Grace FotiadesLifeSci Communications+1. 646.876.5026gfotiades@lifescicomms.com

See the article here:
Nirogy Therapeutics Launches with $16.5 Million Series A FinancingProceeds to support the development of small-molecule drugs that modulate the...

The Anatomy of an African Wild Dog Hunt – PBS

The Anatomy of an African Wild Dog Hunt

Published: January 26, 2021

Narrator: In an African wilderness like Mozambique's Gorongosa National Park, each animal faces a fundamental taskday in, day outfinding something to eat.

Herbivores have an additional challenge: they must also avoid being eaten.

As for carnivores, to survive, they must kill. And to kill, they must hunt.

Paola Bouley: There's some dance that happens between those two groups of species. One doesn't want to be eaten, the other needs to eat. So, they each fulfill a unique niche in the ecology of the system.

Narrator: Two top carnivore species roam the forests and floodplains of Gorongosa: African wild dogs and lions. Each has their own particular style of hunting, and their own unique effect on the prey species around them.

Bouley: A lion is an ambush predator and our lions in Gorongosa tend to hang out in the tall grass and they almost literally wait for something to walk into their mouths. Theyre not out running on the flood plains chasing down prey. They dont have to spend that energy. Theres a stray waterbuck or a warthog thats just walking through the grass and all of a sudden, a lion is there. And it takes a split second for a lion to take it down.

Narrator: Prey are so plentiful in Gorongosa, lion rarely roam from their favorite grasslands, limiting their impact on the ecosystem.

Wide-ranging wild dogs provide an essential contrast.

Bouley: Compared to an ambush predator like a lion, a wild dog is a coursing predator. And that means that it chases down its prey. Its not sitting, lying in wait for something to walk up to its area. Its going to chase down what it wants to consume.

Narrator: Weighing less than eighty pounds, African wild dogs are built for speed and endurance. Their long, thin legs can carry them over a mile during a hunt and propel them at speeds approaching 40 miles an hour.

Bouley: Now, a lion is going to think twice about running after something, especially if they can just pick it out of the grass. But dogs are not stealthy in that sense. Theyre gregarious. Theyre playing together. Theyre noisy. Animals see them coming from far. Theyre not stealthy at all. So, they have to rely on the chasing.

Chasing, clearing, very different strategy to a lion.

Narrator: And there's much more to that strategy than simply out-running prey. The pack's meals emerge from an extraordinary routine.

Bouley: A typical day for the dogs right now is they tend to rest during the heat of the day but in the early mornings and late afternoons they begin to play, socialize more together and they hunt.

Antnio "Tonecas" Paulo: (Translated from Portuguese) About thirty minutes before the hunt, they start playing, and you can see at that stage that they start to lower their heads and prick up their ears a bit and they make a calling sound between them.

Bouley: So, we're looking at some of the best wild dog habit here. It's a wide-open expanse, really flat, hard substrateand they'll course through here.

They start moving across the landscape and then fractions of the pack break off and begin to select prey. Those dogs out in front who want to start hunting are out there already sussing everyone out.

Here we go.

Here in Gorongosa, we have palm thickets, and termite mounds and little patches of forest. Animals like a bushbuck or an oribi would be hunkered in the shade and what we have is a pack of dogs and a wave of teeth that are just sweeping through the landscape, sifting animals out of their refuges, and looking for that one weak moment.

Narrator: Once a victim is flushed out, the wild dogs kick into high gear.

Paulo: (Translated from Portuguese) They chase their prey at a very high speed. When this wave arrives, the prey has little chance to survive the attack.

Bouley: The beauty of a pack is that they function as a whole. Everybody needs to do well together. The sum is greater than the parts with a wild dog pack.

There's no fighting at kills. There's no outward aggression like you'll see with the lion. Everybody gets to eat, nothing is wasted. So, vultures will hang around, but there's very little scraps to be taken. They consume everything.

So, theyre having an impact on how animals are distributing themselves because herbivores understand: thats a predator. They are fulfilling a unique role as a coursing predator in this system. And thats a good thing.

PRODUCER / WRITER

David Murdock

EXECUTIVE PRODUCERS

Jared Lipworth

Sean B. Carroll

EDITOR

Emmanuel Mairesse

NARRATOR

Rodd Houston

DIRECTORS OF PHOTOGRAPHY

Erin Harvey

BRETT KUXHAUSEN

Sound Recordist

Sebastian Dunn

ORIGINAL MUSIC BY

Ivan Mairesse

HEAD OF PRODUCTION & DISTRIBUTION

Anne Tarrant

SUPERVISING PRODUCER

Heather Forbes

DIRECTOR OF OPERATIONS

Lori Beane

COORDINATING PRODUCER

Frank Verock

PRODUCTION MANAGER

Betsy Fielding

ASSOCIATE PRODUCER

Brenda Billoch

POST PRODUCTION SUPERVISOR

Indy Mitra

ASSISTANT EDITOR

Kelsey Johnson

RESEARCHER

Natalia Borrego

SCIENCE EDITOR

Aileen O'Hearn

POST PRODUCTION SERVICES

Henninger Media Services

STOCK FOOTAGE AND ARCHIVE

Gorongosa Media

HHMI Tangled Bank Studios is an initiative of and funded by the HHMI Department of Science Education. Its objective is to advance HHMI's mission of fostering understanding of science.

2020 Tangled Bank Studios, LLC

All Rights Reserved

Follow this link:
The Anatomy of an African Wild Dog Hunt - PBS

Anatomy of the NGO Vaccine Libel – Jewish Journal

Powerful organizations claiming moral agendas have increasingly gained political influence, especially through human rights and international law. In particular, non-governmental organizations (NGOs) with massive budgets for public relations and lobbying have focused worldwide attention on favored targets in some cases with justification, but in others to promote hate and conflict.

Israel has long been a target for demonization based on false claims, and the template NGOs use is familiar.It begins when NGO officials with a history of Israel-bashing launch a campaign based on allegations of dastardly deeds. The facts are twisted or invented, but since they are made by ostensible experts, the media from fringe groups dedicated to the anti-Israel cause to mainstream journalists repeat and amplify these falsities.

NGOs latest accusation is that Israel is violating its legal obligations by failing to provide vaccines to the Palestinians that live under Israeli occupation. As Israels success vaccinating its citizens became more visible and gained praise from around the world, the NGO conspiracy machine went into action, applying their standard template used so successfully in the past twenty years.

NGOs ignored convenient truths, such as the fact that the Palestinian Authority had no interest in Israeli assistance and had already ordered vaccines, in part via Russia and in part through the World Health Organization. Organizations and the media also dismissed the Oslo framework agreement governing relations between Israel and the Palestinian Authority, which states that Powers and responsibilities in the sphere of Health in the West Bank and the Gaza Strip will be transferred to the Palestinian side, including the health insurance system. Acknowledging the reality would have aborted the political campaign before it could get off the ground.

The NGO attack involved numerous organizations, many funded by European governments under the faade of promoting human rights, democracy and international law. The Palestinian Centre for Human Rights and Al Mezan took the lead, issuing a statement under the heading Israel must provide necessary vaccines to Palestinian health care systems and including the hand waving claims attributed to international law.

Officials of both organizations are involved with or linked to the Popular Front for the Liberation of Palestine, a recognized terror group by the United States, the European Union (EU), Canada and other governments. These connections notwithstanding, both NGOs are funded primarily by the EU and western European governments and act as policy subcontractors. In addition, a number of Israeli opposition NGOs promoting the Palestinian narrative and also funded by Europe joined the public relations push.

To get the vaccine campaign out of the fringe anti-Israel arena, global NGO superpowers must enter the fray. Human Rights Watch (HRW) and Amnesty International did exactly that, repeating the accusations word for word. Kenneth Roth, the head of HRW with a long record of singling out Israel tweeted the package of libels to his 350,000 Twitter followers, declaring, the Israeli government has already vaccinated 10% of its citizens .but as the occupying power it has not vaccinated a single Palestinian. Roths second tweet went for the emotional jugular by falsely invoking discrimination: Someone doesnt want you to know about Israels discriminatory treatment of Palestinians in the West Bank and Gaza in distributing the Covid vaccine. Presumably, Roths followers will not know that Israels Arab citizens are receiving vaccinations exactly as their Jewish neighbors do, and that Palestinians outside of Israel are not citizens and have their own government and health system.

To get the vaccine campaign out of the fringe anti-Israel arena, global NGO superpowers must enter the fray.

At this point, the propaganda campaign jumped the tracks to the mainstream media, and from there, was ready to be quoted in the United Nations and by diplomats and politicians. Some outlets and journalists cited the various NGO accusations against Israel verbatim, without bothering to examine their accuracy or relevance. One headline in The Guardian read Palestinians excluded from Israeli Covid vaccine rollout as jabs go to settlers. Others were more circumspect in their coverage, referring to anonymous Legal experts and human rights activists [who] said Israel was obliged to provide the Palestinians with vaccines.

Like many previous NGO campaigns on Israel, the COVID-19 vaccination conspiracy theory is likely to remain and be cited for many years, regardless of the facts or the absence thereof. In 2002, during the height of Palestinian terror bombings, many of the same NGOs led the false allegation of an Israeli massacre and war crimes in the Jenin refugee camp. These attacks remain on their websites and in Wikipedia entries, available for student papers. The same is true for many similar examples in the intervening years, all following the same pattern.

The result is not only more hate directed at Israel and Jews, contributing to violent attacks, but also the continuing erosion of human rights and international law as little more than propaganda tools. For those remaining committed to these principles, confronting the abuses of the ideological NGO industry is essential.

Gerald M. Steinberg is emeritus professor of political science at Bar Ilan University in Israel, and heads the Institute for NGO Research in Jerusalem.

Go here to see the original:
Anatomy of the NGO Vaccine Libel - Jewish Journal

Nektar Appoints Dr. Brian Kotzin as Interim Chief Medical Officer and Head of Development – PRNewswire

"We are pleased that Dr. Kotzin will take on this key role on our development team at Nektar," said Jonathan Zalevsky, Chief R&D Officer of Nektar Therapeutics. "Since he joined Nektar in 2017, Dr. Kotzin has demonstrated strong leadership and strategic insight. He has extensive development experience and over 30 years of expertise in immunology and his strategic guidance will be invaluable toNektaras we continue to execute on development activities for our immune-oncology and immunology pipeline."

Brian Kotzin, MD added, "I am honored to expand my role at Nektar and work alongside Dr. Zalevsky. This is an exciting time for the company with multiple registrational studies underway in a range of tumor types for BEMPEG, a broadening clinical program for NKTR-358 in a number of auto-immune disorders, and an emerging opportunity for NKTR-255 in both hematological malignancies and solid tumors."

While at Nektar, Dr. Kotzin has spearheaded the NKTR-358 development program partnered with Eli Lilly & Co. and he has also served as a development program lead for early development of NKTR-255 and NKTR-262. Dr. Kotzin was previously at Amgen for 11 years, where he served as Vice President, Global Clinical Development and Head of the Inflammation Therapeutic area directing the global development efforts for Amgen product candidates, including all immunology programs. During his tenure at Amgen, he also served as Vice President of Translational Sciences and Head of Medical Sciences/Early Development, where he was responsible for the planning and execution of early-phase clinical development in all therapeutic areas as well as the discovery and implementation of pharmacodynamic biomarkers and clinical immunology support for clinical studies. Prior to joining Amgen, Dr. Kotzin served as Head of Clinical Immunology in the Department of Medicine and as director of the Autoimmunity Center of Excellence at theUniversity of Colorado Health Sciences CenterinDenver. He previously held the position of Professor in the Departments of Medicine, Pediatrics, and Immunology at the National Jewish Medical and Research Center inDenver. In addition to academic posts in rheumatology and microbiology/immunology, Dr. Kotzin served at the Veterans Administration Medical Center inDenveras chief of the Rheumatology Section. Dr. Kotzin received a B.S. in mathematics from the University of Southern California and an M.D. from Stanford University School of Medicine. He completed a residency in internal medicine and a fellowship in rheumatology and medicine at Beth Israel Hospital in Boston. He was also a postdoctoral fellow in the Division of Immunology and Rheumatology at Stanford University School of Medicine. He is board certified in rheumatology and internal medicine.

"Over the past two years, Wei has played a leadership role in recruiting an experienced clinical development organization and executing a late-stage clinical development strategy for BEMPEG, positioning it for future success. I would like to thank him for his contributions to Nektar, and wish him the best in his next opportunity," continued Zalevsky.

About NektarNektar Therapeutics is a biopharmaceutical company with a robust, wholly owned R&D pipeline of investigational medicines in oncology, immunology, and virology as well as a portfolio of approved partnered medicines. Nektar is headquartered in San Francisco, California, with additional operations in Huntsville, Alabama and Hyderabad, India. Further information about the company and its drug development programs and capabilities may be found online at http://www.nektar.com.

Cautionary Note Regarding Forward-Looking StatementsThis press release contains forward-looking statements which can be identified by words such as: "will," "develop," "may" and similar references to future periods. Examples of forward-looking statements include, among others, statements we make regarding the therapeutic potential of bempegaldesleukin (BEMPEG), NKTR-255, NKTR-358, and NKTR-262, as well as the availability of results and outcomes from clinical studies of our drug candidates. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, anticipated events and trends, and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results to differ materially from those indicated in the forward-looking statements include, among others: (i) our statements regarding the therapeutic potential of our drug candidates are based on preclinical and clinical findings and the expected therapeutic potential for each of our drug candidates is subject to change as research and development continue; (ii) our drug candidates are in clinical development and the risk of failure remains high and failure can unexpectedly occur at any stage for one or more of the indications being studied prior to regulatory approval due to lack of sufficient efficacy, safety considerations or other factors that impact drug development; (iii) data reported from ongoing preclinical and clinical trials are necessarily interim data only and the final results will change based on continuing observations; (iv) scientific discovery of new medical breakthroughs is an inherently uncertain process and the future success of potential new drug candidates (such as bempegaldesleukin, NKTR-255, NKTR-358, and NKTR-262) is therefore very uncertain and unpredictable; (v) the timing of the commencement or end of clinical studies and the availability of clinical data may be delayed or unsuccessful due to regulatory delays, slower than anticipated patient enrollment, manufacturing challenges, changing standards of care, evolving regulatory requirements, clinical trial design, clinical outcomes, delays caused by our collaboration partners, and enrollment competition; (vi) patents may not issue from our patent applications for our drug candidates, patents that have issued may not be enforceable, or additional intellectual property licenses from third parties may be required; and (vii) certain other important risks and uncertainties set forth in Nektar's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 6, 2020. Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

Contact:

For Investors:Vivian Wu of Nektar Therapeutics628-895-0661[emailprotected]

For Media:Dan Budwick of 1AB973-271-6085[emailprotected]

SOURCE Nektar Therapeutics

http://www.nektar.com

Read more:
Nektar Appoints Dr. Brian Kotzin as Interim Chief Medical Officer and Head of Development - PRNewswire

Starting Line On Hiatus As We Consider Future – iowastartingline.com

As youve probably noticed, Iowa Starting Line has been rather quiet lately. Ive decided to stop publishing for the time being as I consider significant changes to our operation or whether to continue on at all.

In reality, this hiatus began at the start of December, its just taken me this long to finally write the official post about it. I had intended to only take a personal break for a couple of days, but ended up crashing so hard that Ive barely been able to string together a few sentences for weeks. Working 60 to 80-hour weeks for the past six years straight with practically no breaks probably contributed to that.

This decision is for two reasons, both related to the 2020 election.

The first is financial. While weve had considerable success in building up a news outlet from scratch and expanding it significantly in the past two years, our funding situation is always fluid and comes from different sources each year.

With Democrats getting blown out in Iowa yet again this November, Im concerned about how much left-leaning money will be coming into Iowa in the immediate future. Starting Line was able to expand how it did in part thanks to interest in the Iowa Caucus race and competitive 2020 general election campaigns, along with the advertising revenue that came with those.

If the general mood is that people believe Iowa to be a red-leaning, non-competitive state, getting investments here for the broader progressive infrastructure gets more difficult. I actually think that our race for governor will be very close, but it will probably be early to mid-2022 when some polls come out showing that, and national folks will then engage here in a big way again. My concern for Starting Line is getting through 2021.

As such, if we do continue publishing at Starting Line, the staff will unfortunately be reduced to just myself going forward, though I hope to add back on as things improve. Still, its a very frustrating decision to make, as I very much wanted to keep longterm, permanent positions intact after expanding.

The second reason is with the disappointment in how those November elections turned out not so much that Republicans swept nearly every contested race, but how and why it happened.

Theres three major issues that made this election so particularly demoralizing.

Since 2010, Iowa has experienced four Republican wave years (2010, 2014, 2016 and 2020), one good Democratic year (2018) and one relatively neutral year (2012). This has become an exhausting phenomenon to live through, where it seems that everything gets decided by the national mood or larger factors far outside the control of any person or campaign or issue. So you end up with good public servants that just get wiped out regardless (thats not to say there havent been many bad campaigns run in Iowa there most certainly have its just that the good ones lose too). And then you have total idiots unfit for office elevated by blind party voting.

These wave years have essentially made everything that happens on the ground seem that much less important, including good journalism, which is my next point.

Iowa handled the coronavirus pandemic in 2020 worse than nearly any other government in the entire world, resulting in thousands of unnecessary deaths. And at every step along the way, Iowas press corp held Gov. Kim Reynolds and other leaders feet to the fire, asking tough questions and exposing ways in which the state was covering up the extent of the outbreak and failing to contain it.

And it feels like none of it mattered. Iowans continued to engage in reckless behavior that resulted in killing their neighbors or themselves. And Reynolds and her fellow Republicans were rewarded for their ineptitude we found and heard stories of many first-time voters who came out to support the GOP ticket as a backlash to how they felt COVID changed their lives (despite living in a state with some of the weakest restrictions).

I do want to be clear: I dont think the worth of a Brianne Pfannenstiel or Dave Price or Tony Leys or Kate Payne article rests on whether it costs Republicans votes. Nor does a good piece of journalisms impact need to have anything to do with an election good policy decisions or consequences from reporting can happen regardless of whos in power.

But good lord, youd think Iowas disastrous experience with COVID (or, you know, everything else) would have at least given Iowa voters second thoughts about delivering a massive political win to the party in charge of this mess. It would have been one thing if Joni Ernst and Iowa House Republicans had just barely hung on, where you could attribute the narrow victory to other issues. But Ernsts comfortable victory and Republicans upsets to improve their House majority were striking given the environment they ran in.

There are many, many reasons as to why journalisms impact was limited, all of which we wont even begin to get into here, but the bottom line is this: good journalism should hold the powerful accountable, but it should do so in reality, not just theory. And if voters arent listening to it, then what are we doing here?

When Reynolds held her first press conference after the election, I sat down ready to type up something on it. But as I looked around on Twitter, I noticed how everyone was reporting on her latest COVID briefing in the exact same manner they had before the election. There were the same righteous outrage takes, the same in-depth informative posts on the numbers. We just had an election where voters said resoundingly we dont care to Iowas COVID disaster, and no one was trying to present that information in a different way.

In fairness, there hadnt been much time for reflection yet, but as the weeks drew on, I mostly saw a similar lack of introspection on the political front.

The way Democratic campaigns are run in this state is not working. The longterm infrastructure here is lacking. And many of the suggestions of how to do things differently are the same things Ive heard after 2010, 2014, 2016

So many of the post-2020 takes boiled down to this simply proves what Ive said all along. Others are in denial that anything needs to change (in part because it would mean theyd need to) and are dismissing the election results as solely due to it being a bad year.

I am deeply skeptical that the Democratic campaigns run in 2022 (or the broader party/progressive infrastructure) will look much different from 2020.

So, what to do? I see a couple of different options of what Starting Line and I could do in the future and would be happy to hear your feedback on it. It may be another month or two until we get started back up, as if we do keep going, I would actually like to put deep thought into how we can do things better.

Heres some possibilities:

In some ways, I just want to be done with politics. Ive been involved here in Iowa for nearly 18 years, and I feel like Ive more than done my part. Starting Line has been exhausting, sometimes unrewarding work, and the amount of toxicity you have to put up with in Iowa politics increases every year. It might be nice to have a job with normal hours and reasonable pay for once.

Meanwhile, everything in the U.S. feels like its on a continual downward slide that nothing is going to reverse. And if were really in a lol nothing mattes world, then whats the point of spending all this energy in a broken political system when facts simply dont matter?

And the most depressing aspect is this: if youve followed my work over the years, you know I like to highlight younger political leaders. Regardless of their backgrounds or ideological stances, its good to have fresh eyes and new ways of thinking in politics. But lately, I see some of Iowas up-and-coming leaders making the exact same mistakes their older predecessors did.

Of course, we have built up something important and rather influential here at Starting Line. Making a complete break with it might be good for the mental health, but theres a lot of potential still here. And I unfortunately think that operations like Starting Line could be a big part of the solution to todays news/disinformation problem in politics.

We have quite the property here with Starting Line. I try (and often fail) to explain this to Iowa donors, but Starting Lines influence and national reach with our social media feeds and behind-the-scenes relationships is immense. Nearly every national political reporter follows us. Any time I see an interesting tweet from a national policy leader, elected official, well-known activist or opinion writer, I find that theyre already following us.

For any national news outlet or organization who wanted to make a big jump into Iowa political reporting, purchasing the Starting Line outlet or doing a partnership with us could make a lot of sense.

Like it or not, Iowa always finds its way into the middle of national politics. The Republican presidential primary will likely still start here regardless of what happens with Democrats caucus. The campaigns for the Senate seat and governorship here in 2022 will be important. Starting Line could retain its left-leaning bent or just go straight analytical as it covers all of this for a larger organization.

While Im extremely frustrated by 2020 and the lack of change afterwards in everything, Im also hesitant to just throw out our current model. Ive always tried to keep our focus narrow with Starting Line so that we could be really good at one thing this wasnt ever supposed to revolutionize journalism as we know it or single-handedly change Iowa politics. And we have really excelled at what we do go back and check our accomplishments post in case you missed it.

But if were only playing a role in a larger broken political system, how effective is it? A big part of our success is in influencing the broader Iowa politics conversation and how the media covers certain topics, but if voters arent paying attention to those outlets, what can we accomplish?

Still, I also wonder if this could end up as a situation of you dont know what youve got til its gone if we move away from this model. This past year, Republicans did a far better job at pushing their oppo research on Democrats out to friendly outlets like the Free Beacon, Breitbart, Daily Caller, Fox News and even the Epoch Times. They produced countless stories damaging to Iowa candidates, but it had a limited effect coming from national outlets.

If that continues unchecked, however, we could end up in a situation where right-wing outlets funded by billionaires produce the majority of content on key Iowa races, and that could have a big impact over time.

I also know how to fund this kind of operation, which is extremely cost-efficient for what it produces and accomplishes. If Im feeling more optimistic of where Iowa politics is going in the future, sticking with what were good at (while still constantly working on what we can improve, obviously), might be the smarter thing to do.

One other quick note: if were to continue this, I hope people actually take better advantage of what were producing. Weve written countless stories that you would think campaigns would want to get in front of an audience with digital ads. There are many legislative candidates who weve written up profiles of that would seem to benefit from voters reading them, but instead their Facebook ads are all just replaying their TV ads. I truly dont understand what some Democrats digital teams are thinking if a problem is that there isnt enough news about your candidate, then maybe you should boost the news that is there into peoples social media feeds.

The biggest problem we have right now in American democracy is the spread of misinformation and voters getting trapped in media echo chambers where not only are their views reinforced, they also plain dont hear about a lot of actual news that happens. How many Donald Trump voters will literally never hear of his impeachable phone call to the Georgia Secretary of State from yesterday?

Many in politics do not fully understand the role of what you could call outsider voters, people who are deeply distrustful of the system, dont listen to mainstream news, and who respond strongly to any kind of anti-establishment or anti-expert messaging. Their news comes up in YouTube ads, online forums, and in their social media feed. Those are the kind of people who voted for the first time for Trump and who political ads and factual news articles simply arent getting to.

And its getting easier for people to tune out mainstream news as that news gets harder to access. Newspapers increasingly strict paywalls are dramatically reducing their influence in the world. If the Register has a big investigative report thats a subscriber exclusive that only several tens of thousands of people will read at best, whats its real impact? We know that Reynolds and other Republicans can simply ignore these things when their political base doesnt even know about it or doesnt believe it.

Starting Line does have a very large and rather influential audience, but its largely made up of people already engaged in politics. The most impactful mission we could focus on might be figuring out how to present factual information that is more engaging and trusted by people who are outside the normal political process.

ACRONYM attempted this by establishing local online progressive news outlets and pushing their and others content out through social media ads, which had some fascinating successes and setbacks.

I also have a theory that might be fun to test out: if you make regular news items sound mysterious, they might resonate more with those who distrust the system. I mean, there are legit, real-life, true conspiracies being perpetrated on Iowans all the damn time powerful, wealthy interests working with corrupt or complicit politicians to enrich themselves and screw over working-class people. And yet, the way the news and political campaigns present these facts somehow get dismissed by voters who at the same time believe wild Q-Anon theories about every elected official being involved in a child sex trafficking ring.

Anyway, this approach would require a significant retooling of how we write and who our audience is, which would abandon some of the advantages weve built up over six years. And this idea also veers very close to my concern of trying to do too much can one news outlet with a small or one-person staff fundamentally change how a significant number of Iowans get their news? Im not so sure, but it might be worth it to try.

5. Investigative News

Perhaps what I would personally enjoy most is doing a one-man investigative site, spending days and weeks at a time digging into stories no one else is and uncovering what I can discover. Dont worry about website traffic, just break stories that people cant ignore. Theres many little unsolved threads from Iowas COVID pandemic that we didnt have enough time to chase down even with a full staff.

But, as discussed above, how much impact would it have if so many people can just ignore it or would never see it through our site or even mainstream news outlets? Im also less sure how to fund this approach.

6. YOLO It

I am not happy with how Democratic campaigns are run in this state. I am not happy with how nothing ever changes cycle to cycle.

Throughout this past year, I expressed my concerns and suggestions to friends who work on campaigns privately. Sometimes it has an effect, sometimes it doesnt. My own personal preference is to not put people on public blast on decisions that have already been made, where your criticism isnt going to change anything I personally see that as performative, but to each their own. People also simply cannot handle public constructive criticism in any manner, and I cannot single-handedly change human behavior on that front.

However, the number of bad strategies that get repeated year in and year out is just ridiculous, and I may have finally hit my breaking point. There are many individual bad actors in Iowa politics that need to get called out and see their influence reduced or removed, and I certainly know who those people are.

The problem is, would it actually change anything? The power of self-interest in literally everything is strong, and doing a one-man crusade against it, as good as it may feel to do, could go nowhere. And I certainly dont see other folks making sacrifices, so why should I?

As always, Ill end with a very big thank you to our readers and supporters over the year. Continuing to write and operate just for our many loyal fans is very nearly worth it alone. But we do have some decisions to make.

While we likely wont get back to regular publishing for a month or two (if we do at all), Ill probably write stories every now and then or post some guest pieces. With this overly-long piece out of the way, it may be easier to write up some of the many, many ideas Ive had since the election that I simply havent had the energy to do.

by Pat RynardPosted 1/4/21

Iowa Starting Line is an independently owned progressive news outlet devoted to providing unique, insightful coverage on Iowa news and politics. We need reader support to continue operating please donate here. Follow us onTwitterandFacebookfor more coverage.

Link:
Starting Line On Hiatus As We Consider Future - iowastartingline.com

New Year’s Eve Parties in Los Angeles: It’s Happening – The New York Times

Prohibition in the United States, a short-lived experiment that began 100 years ago, popularized the speakeasy: an illicit establishment designed to sell alcoholic beverages during the years they were legally banned.

Now, people are developing clandestine social clubs all over again and even styling their parties after the era of speakeasies.

Thats true even in Los Angeles, where more than 14,000 positive coronavirus tests are being reported in a day, and where the public health risks of going to a party seem too obvious to let partygoers remain in denial.

For the record: The Centers for Disease Control and Prevention recommends celebrating at home, wearing a mask around others and definitely avoiding crowds.

Throughout the pandemic, well-attended parties have mostly been shut down across Los Angeles, which has led to a culture of secrecy on social media. At the same time, underground party hosts are choosing to appeal to the truth of human behavior. They know that they can capitalize on the innate desire to socialize; for all those who cant imagine leaving their homes right now, there are others who are fully ready to celebrate the arrival of 2021 in the company of near strangers, as they would any other year.

These New Years Eve parties in Los Angeles include Spankys, which promises a laid-back affair at an indoor/outdoor venue downtown. The price of admission includes a 10 min Covid-19 antigen test, according to the invite. (While testing may weed out some people with coronavirus, it isnt a foolproof method. For one thing, rapid tests have a higher potential for false positives, according to the F.D.A.)

Chloe Chappe, 26 and a private chef in Los Angeles, has been getting Spankys emails since July and doesnt know how she ended up on their mailing list. I find it funny and frustrating that people are trying to justify partying right now, she said. Why are you trying to party when theres such a severe level of infection rates?

In many cases, revelry has been traded for discretion. People are not posting things because they know how much backlash theyll get, Ms. Chappe said. Being deprived of that kind of interaction for almost a year, I completely understand why people would want to finally celebrate this year being over, but were not at that point safety-wise, so theres such a dissonance there.

Cherrelle Moore, 28 and a freelance creative from New York celebrating New Years Eve in Los Angeles, has been visiting California for about a month. She said she has been to four or five house parties, and one strip club during that time. Ms. Moore plans to see people on the eve of 2021 but to limit her night to a low-key house party.

People think you going out is just being irresponsible, but it feels good and warm and good for your mental health too sometimes to be around people you love and even meet new people too you just have to be responsible, she said. She estimated shed been tested more than 15 times almost every other week, especially because I was in big gatherings.

Ms. Moore said she has never had coronavirus Thank God and that she believes theres a line of communication and trust required to socialize safely during the pandemic. And while she does post about it on social media, she noticed that it seemed like people were shading me and her friends as well, so she started posting only to her private Instagram network of close friends instead.

The reason why I even left New York was because I felt like I was about to go into a deep hole of depression again. I came out here for friends. I just didnt feel like staying in New York for the new year to come, Ms. Moore said. We can agree to disagree, but life is so short. It may sound irresponsible, but Im just going to live my life. Ive been super cautious and responsible this whole time, so Im going to try to turn up and manifest for 2021 and hopefully its way better than this year.

She is not alone.

An iOS app called Vybe Together encouraged users to Get your rebel on and Get your party on, and was designed to organize and promote underground parties to its audience. It seemed particularly well designed to facilitate parties that would violate current restrictions.

After it received attention this week, its website went down and Apple pulled the app from its store on Tuesday. (Business Insider reported that TikTok also removed the companys account.) We kinda blew up over night, said someone who answered Vybe Togethers phone. (The owners declined to speak further.)

The app had only a few thousand users, though there were thousands more waiting for their access to be approved.

Vybe Together updated its Instagram bio amid the trouble: App Store took us down!!! We will be back!!! Follow to stay updated!!! A minimal text post appeared on the accounts Instagram story: blown out of proportion by the media. We DO NOT CONDONE LARGE GATHERINGS!!!

Eventbrite, an event management and ticketing platform, has also been a popular option for people hosting parties. A recent Maskerade at a Los Angeles mansion ($80, open bar, round-trip party-bus ride) was advertised there. The invite, which drew ire on social media, has been removed from Eventbrites website.

Several other parties to be held at popular Los Angeles nightlife venues (such as Bootsy Bellows and Harriets Rooftop) were also listed on Eventbrite but are now marked as canceled. Blind Dragon, a venue listed as closed on OpenTable, promised a premium open bar beginning at 9 p.m. Gatsbys House NYE in Huntington Beach had tickets starting at $99 and topping out at $3,795. An event at Skybar, on the roof of the Mondrian in West Hollywood, promised a special live D.J. performance.

Our Community Guidelines have always prohibited events that promote or contain illegal behavior and our community plays an essential role in reporting any concerning event listings or content, a spokesperson for Eventbrite said in a statement. The company investigates complaints and says it wants to foster digital gatherings during the pandemic.

In the absence of our ability to bring people together for in-person experiences, we moved fast to help creators take their experiences online, said Julia Hartz, a founder and the chief executive of Eventbrite.

Those who wish to party anyway will return to finding celebrations the retro way: through private Instagrams, DMs and invites with no downloadable details, just an address thatll be texted out before midnight along with a request to wear a mask.

Earlier this month, the Los Angeles city attorneys office filed a lawsuit against the manager of LA Party Society, a nightclub in Downtowns Fashion District, and others associated with the venue for holding crowded events amid a surging pandemic, said Mike Feuer, the Los Angeles city attorney, in a virtual news conference.

As of now, the citys revised targeted safer at home order is clear. It states that all public and private gatherings and events with people from more than one household are not permitted except for outdoor faith-based services and outdoor political expression and that all lounges and nightclubs are to be closed.

Go here to read the rest:
New Year's Eve Parties in Los Angeles: It's Happening - The New York Times

Grey’s Anatomy: 10 Movies Starring The Cast | ScreenRant – Screen Rant

Before they achieved critical fame on Grey's Anatomy, these actors starred in several feature movies and hit films.

Today, Greys Anatomyhas one of the longest-running tv shows of all time. Created by Shonda Rhimes,the medical dramafocuses on its characters and the personal drama that they bring to each episode. There is also plenty of laughs, drama, intriguing storylines, and cleverly crafted dialogue that fans have thoroughly enjoyed too.

RELATED: Grey's Anatomy: Shortest Running Cast Members

As far as the cast goes, the show also boasts of one of the largest assemblies of on television. With over 200 main characters, it's not surprising if some of its cast look quite familiar. In some cases, these cast members have also appeared in some hit movies, including:

Before she ever landed the titular role on Greys Anatomy, Ellen Pompeo worked on a number of feature films early on in her career. Among them was this 2002 drama that also stars Dustin Hoffman, Susan Sarandon, and Jake Gyllenhaal.

In the movie, Pompeo and Gyllenhaal cross paths as Gyllenhaal mourns the death of his fianc. While recalling Pompeos audition for the movie, Gyllenhaal told the Los Angeles Times, And she blew the audition out of the water. Interestingly, the two also had a brief encounter shortly before they learned that they would be working on this movie together.

This 2002 movie is considered one of the best cat and mouse films today. Catch Me If You Can boasts of a cast that includes Tom Hanks, Leonardo DiCaprio, Amy Adams, Martin Sheen, and Christopher Walken. The movie also stars Pompeo. However,it's sort of one of those blink-and-you-miss-it appearances.

The actress appears briefly in a scene as a flight attendant, a role that Spielberg had offered to her. While speaking with Los Angeles Times, Pompeo recalled, And I graciously accepted. And screamed all the way home.

In this 2002 romantic comedy, Reese Witherspoon plays a New York City socialite who needs to return to Alabama to get a divorce from her estranged husband. In the movie, Patrick Dempsey plays Witherspoons ideal fianc while Josh Lucas plays the man she cant wait to divorce. In 2019, there was talk of a possible sequel.

While on Good Morning America, Lucas said theres a proposed storyline where Dempseys character is still in the picture. According to USA Today, Witherspoon has said she would happily make Sweet Home Alabama 2.

In this 2007 comedy, Greys Dempsey plays a single father who meets a woman from a fairy tale world. Of his role, the actor admits that he found it to be both fun and challenging. Dempsey even told Cinema.com, There were times when I wanted to put the scrubs back on and go back to Greys Anatomy because I kept worrying that I was too serious or not funny enough.

RELATED:The 10 Best Idina Menzel Performances, According To Rotten Tomatoes

Interestingly, Dempseys leading lady was also supposed to be Witherspoon. The role eventually went to Amy Adams.

Sideways is a critically acclaimed film about two men who decide to make a trip to Californias wine country just before one of them gets married. In the movie, Greys Sandra Oh plays a single mom. While discussing the film, Oh told Entertainment Weekly, In Sideways, I have maybe 15, 20 lines. But because of the way the film is written, you never see anyone as a sidekick or a girlfriend.

Sideways went on to score several Oscar nods and an Oscar win for best-adapted screenplay. It is also known as one of Alexander Paynes best movies.

This 2010 movie centers on a dancer who is dealing with a multiple personality disorder. Frankie & Alice stars Halle Berry, Stellan Skarsgrd, Phylicia Rashad, and Greys Chandra Wilson. While discussing the movie withShock Ya!, Wilson revealed that she wanted to do the film because of the cast.

RELATED:Grey's Anatomy: 10 Hidden Details About Miranda Bailey Everyone Missed

The actress even jokingly remarked, So in a way, it didnt matter what the project was going to be. Meanwhile, Wilson also revealed that she only had a few days to shoot her scenes for the movie because of her Greys schedule.

In a similar structure to Love Actually,Valentine's Dayfollowed the lives of several characters. One of the stories sees Sean (Eric Dane), who is a closeted gay football star attempt to save his relationship with his boyfriend (Bradley Cooper) after tensions between them become too much.

Dane wasn't the onlyGrey'sstar to feature in the movie either.Patrick Dempsey also appears, playing a cardiothoracic surgeon, who is also the boyfriend of Jennifer Garner's character. In an ironic twist, he is also revealed to be married.

The 2009 sequel stars Chris Carmack as a man who uses his power to time travel and solve the mystery surrounding the death of his girlfriend.

RELATED:10 Things That Make No Sense About The Butterfly Effect

Aside from playing the lead role in the movie, Carmack also contributed behind the scenes, specifically when it came to some of the background music. I was working with director Seth Grossman and he had mentioned he wanted to put some bluesy type tunes in the background of some of the bar scenes, Carmack told Media Mikes. He asked if I had any music he could use and I told him I did

The November Man stars Pierce Brosnan as a former CIA agent, who takes on a personal mission and finds himself going up against a former pupil. The movie also stars Greys Anatomys Caterina Scorsone as Celia, who plays a CIA official.

The November Man came out around the time that Scorsones stint in the Greys spinoff, Private Practice, had ended. As interesting as the premise of the movie may seem, The November Man received lackluster reviews from critics. There is consensus that the movie just utilizes a lot of spy action-thriller clichs.

In this comedy, Ben Stiller plays a security guard who works at a museum where figures come alive at night. The movie also stars Kim Raver as Stillers ex-wife. Around the time that Raver was working on the movie, she was yet to join the cast of Greys. That said, she was starring in the series 24.

Night at the Museum may be seen as a great family movie, but many say that it also features one of the worst graphics, especially when it comes to the mummies. However, as long as kids are watching, many fans dont mind that Rami Malek is playing a not-so-scary mummy.

NEXT:Ben Stiller: 5 Family-Friendly Movies (& 5 Surprisingly Dark Ones)

Next 10 Dorm Rooms From Popular Movies & TV Shows Fans Wish They Had

Here is the original post:
Grey's Anatomy: 10 Movies Starring The Cast | ScreenRant - Screen Rant